Male, Female V1421 Carriers Face Similar Risk for Heart Failure Hospitalization
By Elana Gotkine HealthDay Reporter
THURSDAY, May 16, 2024 -- Male and female V1421 carriers face a similar and substantial risk for heart failure hospitalization, according to a study published online May 12 in the Journal of the American Medical Association to coincide with the European Society of Cardiology Heart Failure 2024, held from May 11 to 14 in Lisbon, Portugal.
Noting that individual studies have indicated that the amyloidogenic V1421 variant of the transthyretin gene increases heart failure and mortality risk, Senthil Selvaraj, M.D., from the Duke University Medical Center in Durham, North Carolina, and colleagues examined the natural history of disease in carriers across mid to late life. Data were included for 23,338 self-reported Black participants initially free from heart failure; 3.2 percent were V1421 carriers.
The researchers found that 10-year carrier risk increased for heart failure hospitalization by 63 years of age, which was mainly driven by heart failure with reduced ejection fraction; the 10-year all-cause mortality risk increased by 72 years of age. Risk with the variant was only modified by age, but not sex or other select variables, with estimated reductions in longevity varying from 1.9 to 2.8 years at ages 50 and 81 years, respectively. Based on these data, due to the variant, 435,851 estimated U.S. Black carriers between ages 50 and 95 years were projected to cumulatively lose 957,505 years of life.
"Male and female V1421 carriers faced similar and substantial risk for HF hospitalization, predominantly with reduced ejection fraction, and all-cause death later in life, with steep age-dependent penetrance," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mortality in Rheumatic Heart Disease Is High
FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer
FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.